Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDiaceutics Regulatory News (DXRX)

Share Price Information for Diaceutics (DXRX)

Share Price is delayed by 15 minutes
Get Live Data
138.00    -3.50 (-2.47%)
Bid:
136.00
Ask:
140.00
Spread: 4.00 (2.941%)
Market Cap: £116.79m
DXRX Live PriceLast checked at - London Stock Exchange

Intraday Diaceutics Share Chart

PDMR Shareholding/SIP & Total Voting Rights

31 Oct 2023 12:38

RNS Number : 8967R
Diaceutics PLC
31 October 2023
ย 

ย 

31 October 2023

Diaceutics PLC

ย 

PDMR Shareholding/Share Incentive Plan and Total Voting Rights

ย 

Diaceutics PLC, (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, has been notified that on 27 October 2023, Global Shares Trustees (UK) Limited (the "UK Trust") and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares of ยฃ0.002 in the capital of the Company ("Shares") on behalf of Susanne Munksted, Jordan Clark, Julie Browne, Nick Roberts and Jillian Beggs (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employees. These purchases will be made each month until further notice.

ย 

In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.

ย 

As announced on 2 October 2023, application was made to AIM for a block listing of 1,500,000 Shares to facilitate the admission of the Shares to trading following the exercise of options inter alia under the SIP Schemes. Therefore, the matched share awards for the UK PDMRs, along with those for all other participants in the UK SIP Scheme, have been settled by the Company issuing 10,299 Shares on 27 October 2023 to the UK Trust. The Trust will hold these Shares on behalf of participants until they vest in accordance with the UK Scheme rules.

ย 

Following the issue of Shares on 27 October, Diaceutics has 84,491,926 Shares in issue. This figure may be used by shareholders in the Company as a denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

ย 

Enquiries:

ย 

Diaceutics PLCย 

ย 

Tel: +44 (0)28 9040 6500ย 

Nick Roberts, Chief Financial Officerย 

investorrelations@diaceutics.com

Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison

Nick Harland

Kate Hanshaw

Alma PR

Tel: +44(0)20 3405 0205

Caroline Forde

diaceutics@almapr.co.uk

Matthew Young

Kinvara Verdon

About Diaceutics

ย 

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

ย 

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ยฎ

ย 

ย 

ย 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Susanne Munksted

2

Reason for notification

a.

Position/Status

Chief Precision Medicine Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of ยฃ0.002 each

ย 

ISIN: ย GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)

Share purchase:

Price(s)

Volume(s)

0.88 p

172

Conditional share award:

Price(s)

Volume(s)

Nil

172

e.

Date of the transaction

Share purchase and Conditional share award: 27 October 2023

f.

Place of the transaction

Share Purchase: AIM Market of the London Stock Exchange

Conditional share award: Off-Market

ย 

ย 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jordan Clark

2

Reason for notification

a.

Position/Status

Chief Data Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of ยฃ0.002 each

ย 

ISIN: ย GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)

Share purchase:

Price(s)

Volume(s)

0.88 p

170

ย Matched share award:

Price(s)

Volume(s)

Nil

170

e.

Date of the transaction

Share purchase and Matched Share award: 27 October 2023

f.

Place of the transaction

Share Purchase: AIM Market of the London Stock Exchange

Matched Share Award: Off-Market

ย 

ย 

ย 

ย 

ย 

ย 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Julie Browne

2

Reason for notification

a.

Position/Status

Chief Operations Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of ยฃ0.002 each

ย 

ISIN: ย GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)

Share purchase:

Price(s)

Volume(s)

0.88 p

170

ย Matched share award:

Price(s)

Volume(s)

Nil

170

e.

Date of the transaction

Share purchase and Matched Share award: 27 October 2023

f.

Place of the transaction

Share Purchase: AIM Market of the London Stock Exchange

Matched Share Award: Off-Market

ย 

ย 

ย 

ย 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Nick Roberts

2

Reason for notification

a.

Position/Status

Chief Finance Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of ยฃ0.002 each

ย 

ISIN: ย GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)

Share purchase:

Price(s)

Volume(s)

0.88 p

170

ย Matched share award:

Price(s)

Volume(s)

Nil

170

e.

Date of the transaction

Share purchase and Matched Share award: 27 October 2023

f.

Place of the transaction

Share Purchase : AIM Market of the London Stock Exchange

Matched Share Award: Off-Market

ย 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jillian Beggs

2

Reason for notification

a.

Position/Status

Chief Commercial Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary shares of ยฃ0.002 each

ย 

ISIN: ย GB00BJQTGV64

b.

Nature of the transaction

Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")

c.

Price(s) and volume(s)

Share purchase:

Price(s)

Volume(s)

0.88 p

170

ย Matched share award:

Price(s)

Volume(s)

Nil

170

e.

Date of the transaction

Share purchase and Matched Share award: 27 October 2023

f.

Place of the transaction

Share Purchase : AIM Market of the London Stock Exchange

Matched Share Award: Off-Market

ย 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ย 
END
ย 
ย 
DSHEAAEFDDSDFFA
Date   Source Headline
1st Jun 20262:00 pmRNSPDMR Shareholding/Share Incentive Plan & TVRs
29th May 20262:00 pmRNSNotice of AGM & Posting of Annual Report
26th May 20267:00 amRNSFinal Results
13th May 20267:00 amRNSNotice of Results
12th May 20262:00 pmRNSHolding(s) in Company
5th May 20267:00 amRNSPDMR Shareholding/Share Incentive Plan and TVRs
16th Apr 20261:11 pmRNSRelated Party Transaction - Lease Extension
7th Apr 20267:00 amRNSBlock Listing Return
1st Apr 202611:59 amRNSPDMR Shareholding/SIP & Total Voting Rights
3rd Mar 202610:56 amRNSPDMR Shareholding/Share Incentive Plan and TVRs
3rd Feb 20268:01 amRNSPDMR Shareholding/Share Incentive Plan & TVR
15th Jan 20267:00 amRNSFull Year 2025 Trading Update
23rd Dec 20257:00 amRNSPDMR Shareholding/SIP & Total Voting Rights
23rd Dec 20257:00 amRNSPDMR Shareholding/SIP & Total Voting Rights
28th Nov 202511:53 amRNSPDMR Shareholding/SIP & Total Voting Rights
4th Nov 20257:00 amRNSPDMR Shareholding/Share Incentive Plan and TVR
7th Oct 20257:00 amRNSBlock listing Interim Review
1st Oct 202511:40 amRNSPDMR Shareholding/Share Incentive Plan and TVR
23rd Sep 20257:00 amRNSH1 2025 Results
11th Sep 20257:00 amRNSNotice of Results
9th Sep 202510:47 amRNSHolding(s) in Company
2nd Sep 20257:00 amRNSPDMR Shareholding/Share Incentive Plan and TVR
11th Aug 202510:58 amRNSHolding(s) in Company
5th Aug 20257:00 amRNS-RDiaceutics at Canaccord Genuity Growth Conference
30th Jul 20257:00 amRNSPDMR Shareholding/Share Incentive Plan and TVR
29th Jul 20257:00 amRNS-RDiaceutics Announces Key Leadership Appointment
25th Jul 202512:15 pmRNSHolding(s) in Company
23rd Jul 20257:00 amRNSIssue of Share Options / PDMR Shareholdings
22nd Jul 20257:00 amRNS22% Revenue Growth H125 representing 3-yr CAGR 25%
17th Jul 20257:00 amRNS-RExpansion of PMx Commercialization Partnership
30th Jun 20257:00 amRNSPDMR Shareholding/SIP and Total Voting Rights
18th Jun 202512:00 pmRNSResults of AGM
6th Jun 20259:33 amRNSPDMR Shareholding /Share Incentive Plan and TVR
21st May 20255:00 pmRNSNotice of AGM and Posting of Annual Report
15th May 20257:00 amRNSTransaction by Persons Closely Associated to PDMRs
13th May 20257:00 amRNSFY 2024 Results - Strong Revenue Growth
29th Apr 20254:09 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
29th Apr 20257:00 amRNSNotice of Results
7th Apr 202510:33 amRNSBlock Listing Return
3rd Apr 20251:54 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
26th Mar 20257:00 amRNSPMx Promotional Partner Contract Enhancement
6th Mar 20253:16 pmRNSHolding(s) in Company
3rd Mar 20253:00 pmRNSPDMR Shareholding/Share Incentive Plan and TVR
31st Jan 20259:13 amRNSPurchase of Shares and PDMR Shareholding
30th Jan 202511:27 amRNSPDMR Shareholding/Share Incentive Plan
28th Jan 20257:00 amRNSFY 2024 Trading Update - Strong Revenue Growth
14th Jan 20257:00 amRNSDiaceutics Opens US Headquarters
8th Jan 20257:00 amRNSNew Service Launched & First Contract Signed
3rd Jan 20253:39 pmRNSPDMR Dealings & Total Voting Rights
19th Dec 20248:09 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.